BR112018008882A2 - método para tratar um distúrbio proliferativo e produto farmacêutico - Google Patents

método para tratar um distúrbio proliferativo e produto farmacêutico

Info

Publication number
BR112018008882A2
BR112018008882A2 BR112018008882A BR112018008882A BR112018008882A2 BR 112018008882 A2 BR112018008882 A2 BR 112018008882A2 BR 112018008882 A BR112018008882 A BR 112018008882A BR 112018008882 A BR112018008882 A BR 112018008882A BR 112018008882 A2 BR112018008882 A2 BR 112018008882A2
Authority
BR
Brazil
Prior art keywords
treating
pharmaceutical
proliferative disorder
patient
combination therapy
Prior art date
Application number
BR112018008882A
Other languages
English (en)
Other versions
BR112018008882A8 (pt
Inventor
Sampath Deepak
Han Lina
Yurievna Konopleva Marina
Merchant Mark
Original Assignee
Univ Texas
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Genentech Inc filed Critical Univ Texas
Publication of BR112018008882A2 publication Critical patent/BR112018008882A2/pt
Publication of BR112018008882A8 publication Critical patent/BR112018008882A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

a presente invenção é dirigida a uma terapia de combinação envolvendo um inibidor seletivo de bcl-2 e um inibidor de mek para o tratamento de um paciente com necessidade de tal terapia. o paciente que necessita da terapia de combinação está sofrendo de câncer, tal como leucemia mieloide aguda.
BR112018008882A 2015-11-03 2016-11-03 método para tratar um distúrbio proliferativo e produto farmacêutico BR112018008882A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562250231P 2015-11-03 2015-11-03
US201562263082P 2015-12-04 2015-12-04
PCT/US2016/060271 WO2017079399A1 (en) 2015-11-03 2016-11-03 Combination of bcl-2 inhibitor and mek inhibitor for the treatment of cancer

Publications (2)

Publication Number Publication Date
BR112018008882A2 true BR112018008882A2 (pt) 2018-11-06
BR112018008882A8 BR112018008882A8 (pt) 2019-02-26

Family

ID=57471995

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018008882A BR112018008882A8 (pt) 2015-11-03 2016-11-03 método para tratar um distúrbio proliferativo e produto farmacêutico

Country Status (13)

Country Link
US (2) US10959993B2 (pt)
EP (1) EP3370775B1 (pt)
JP (1) JP6724136B2 (pt)
KR (1) KR102124715B1 (pt)
CN (1) CN108601839B (pt)
AU (1) AU2016349279A1 (pt)
BR (1) BR112018008882A8 (pt)
CA (1) CA3001880C (pt)
HK (1) HK1259545A1 (pt)
IL (1) IL258741B (pt)
MA (1) MA43170A (pt)
MX (1) MX2018005233A (pt)
WO (1) WO2017079399A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6408993B2 (ja) * 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
GB201809746D0 (en) * 2018-06-14 2018-08-01 Berlin Chemie Ag Pharmaceutical combinations
TW202023568A (zh) * 2018-07-30 2020-07-01 瑞典商阿斯特捷利康公司 用於治療癌症之組合療法
CN113194946A (zh) * 2018-10-16 2021-07-30 约翰斯·霍普金斯大学 用于治疗血管性埃勒斯-当洛斯综合征和有关障碍的组合物和方法
WO2020181219A1 (en) * 2019-03-06 2020-09-10 The Regents Of The University Of Colorado, A Body Corporate Methods of detecting and treating venetoclax-resistant acute myeloid leukemia
AU2020265225A1 (en) * 2019-04-29 2021-10-28 Immunogen, Inc. Therapeutic combinations comprising anti-CD123 immunoconjugates
WO2020247275A2 (en) * 2019-06-03 2020-12-10 Sanford Burnham Prebys Medical Discovery Institute Uses of synthetic lethal partners for treatment of cancer
WO2022014025A1 (ja) * 2020-07-17 2022-01-20 Ｄｅｌｔａ－Ｆｌｙ Ｐｈａｒｍａ株式会社 血液がんの新規治療法及び新規治療剤

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA019983B1 (ru) 2005-10-07 2014-07-30 Экселиксис, Инк. Ингибиторы mek и способы их применения
JP2011519868A (ja) * 2008-05-05 2011-07-14 シェーリング コーポレイション 癌を処置するための化学療法剤の連続投与
WO2009151569A2 (en) * 2008-06-09 2009-12-17 Combinatorx, Incorporated Beta adrenergic receptor agonists for the treatment of b-cell proliferative disorders
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
EP2632436B1 (en) 2010-10-29 2018-08-29 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
WO2012071374A1 (en) 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors
US8722657B2 (en) 2010-11-23 2014-05-13 Abbvie Inc. Salts and crystalline forms of an apoptosis-inducing agent
JP6058009B2 (ja) * 2011-08-31 2017-01-11 ノバルティス アーゲー Ｐｉ３ｋ−およびｍｅｋ−阻害剤の相乗的な組合せ
ES2743427T3 (es) 2012-08-17 2020-02-19 Hoffmann La Roche Politerapias para melanoma que comprenden administrar cobimetinib y vemurafinib
JP6408993B2 (ja) 2012-09-07 2018-10-17 ジェネンテック， インコーポレイテッド タイプＩＩ抗ＣＤ２０抗体と選択的Ｂｃｌ−２インヒビターの併用療法
US10111897B2 (en) * 2013-10-03 2018-10-30 Duke University Compositions and methods for treating cancer with JAK2 activity

Also Published As

Publication number Publication date
JP6724136B2 (ja) 2020-07-15
US20180303815A1 (en) 2018-10-25
US20210169865A1 (en) 2021-06-10
CA3001880C (en) 2021-08-17
MX2018005233A (es) 2019-04-29
IL258741B (en) 2021-08-31
HK1259545A1 (zh) 2019-11-29
KR102124715B1 (ko) 2020-06-18
CN108601839B (zh) 2021-10-26
EP3370775A1 (en) 2018-09-12
AU2016349279A1 (en) 2018-05-10
WO2017079399A1 (en) 2017-05-11
JP2018534298A (ja) 2018-11-22
IL258741A (en) 2018-06-28
MA43170A (fr) 2018-09-12
US10959993B2 (en) 2021-03-30
BR112018008882A8 (pt) 2019-02-26
CN108601839A (zh) 2018-09-28
EP3370775B1 (en) 2023-04-19
CA3001880A1 (en) 2017-05-11
KR20180054852A (ko) 2018-05-24

Similar Documents

Publication Publication Date Title
BR112018008882A8 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
BR112018013731A2 (pt) combinações anti-egfr para o tratamento de tumores
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
CL2018003123A1 (es) Terapia de combinación para el tratamiento del cáncer
BR112018013733A2 (pt) combinações anti-cd20 para o tratamento de tumores a
MX2018016193A (es) Métodos para el tratamiento del cáncer de ovario.
PH12017500070A1 (en) Methods of treating cancer using tigit inhibitors and anti-cancer agents
UY36307A (es) Terapias combinadas para el tratamiento del cáncer
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
DOP2017000268A (es) Metodos y kits para tratar depresion
MA39906A (fr) Polythérapies pour le traitement du cancer
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
EA201992251A1 (ru) Противораковые вакцины и способы лечения с их применением
BR112017023517A2 (pt) anticorpo anti-cd20 para tratamento do câncer, composição farmacêutica, método de tratamento de um paciente que sofre de câncer e uso de um anticorpo anti-cd20
BR112015026297A2 (pt) terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer
BR112017021312A2 (pt) tratamento de câncer de pulmão com inibidores de glutaminase
EA201791736A1 (ru) Комбинированная терапия для лечения рака
BR112019001398A2 (pt) métodos para tratamento de câncer de próstata
BR112018000776A2 (pt) métodos para tratamento de câncer usando apilimod
PH12017501879A1 (en) Methods for treating cancer
MX2019013808A (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
MX2016015378A (es) Uso de eribulina en el tratamiento de cancer.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2747 DE 29-08-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.